Wipro Limited, a prominent worldwide information technology, consulting, and business process services firm, and Pandorum Technologies, a biotechnology firm specializing in tissue engineering and regenerative medicine, announced a long-term cooperation today. The firms will collaborate on the development of technologies that will reduce time-to-market and improve patient outcomes in regenerative medicine R&D and clinical trials. Wipro Holmes’ Artificial Intelligence (AI) capabilities are combined with Pandorum’s regenerative medicine knowledge in this alliance.
The cooperation will initially focus on ‘bio-engineered liquid cornea,’ but it will eventually expand to include lung and liver regenerating tissues.
The Wipro Holmes AI-based decision support system will provide information on the prospective outcomes of specific formulations, use advanced algorithms to forecast and increase therapeutic efficacy, and assist in clinical study design.
Pandorum and Wipro have teamed together to create an AI system that can learn from multi-dimensional data from Pandorum’s R&D pipeline at the cellular, tissue (organoid), and organ levels and deliver actionable insights. Pandorum’s state-of-the-art skills in tissue regeneration and regenerative medicine will be complemented by Wipro Holmes’ capacity to derive insights from phenotypes, genotypes, and clinical progression evaluations. Pandorum is about to enter clinical trials, and the company’s exponential partnership with Wipro, which combines Pandorum’s expertise with artificial intelligence, will unleash the power of regenerative medicine.
“By embracing digital technologies such as artificial intelligence, life sciences organizations can accelerate innovation, transform business processes, and fuel growth. In life sciences R&D, AI is particularly valuable to rapidly discover new formulations, expedite therapeutic development and bring life-saving therapies to market faster, thereby positively influencing human health. With our domain and AI expertise, we stand ready to enable our health and life sciences clients to serve their stakeholders better,”said Rajan Kohli, President and Managing Partner, iDEAS, Wipro Limited.
“We’re living in a time of unprecedented progress in biology, data science and machine learning. We are building a framework to converge these three fields, in order to harness the potential of tissue reprogramming to the fullest and address global unmet clinical needs, such as, corneal blindness, Liver diseases. In the end, what matters most is to be able to alleviate the suffering of the patients. Together with Wipro, we hope to accelerate this process”said Tuhin Bhowmick, Co-founder & Chief Executive Officer, Pandorum.
“Regenerative medicine is an alternative option for many patients awaiting donors for transplant. We are excited to bring Wipro Holmes advanced AI capabilities to Pandorum, which will accelerate the development of successful regenerative therapeutics and enable better outcomes for the patients. Our focus on developing explainable AI and built-in capabilities for data privacy makes Wipro Holmes the most suitable for life sciences R&D and clinical trials,”said Harmeet Chauhan, Global Head – Engineering and R&D, Wipro Limited.